Oxford Biomedica initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Rick Bienkowski initiated coverage of Oxford Biomedica with an Overweight rating and 840 GBp price target. While the company has lost a valuable revenue stream after completing the production of Vaxzevria in 2022, the firm sees an attractive growth story where the company’s expertise in viral vector production will help to capture share in a growing market for external manufacturing of gene therapies, the analyst tells investors in a research note. Its entry into the adeno-associated virus manufacturing market provides a large opportunity for revenue growth, and Cantor sees a path to profitability by 2026E.